Benitec Biopharma
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
- Conditions
- Oculopharyngeal Muscular Dystrophy
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Benitec Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06185673
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Benitec Biopharma, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03433027
- Locations
- 🇦🇺
The Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia
🇷🇺Irkutsk Oncology Center, Irkutsk, Russian Federation
News
Benitec Biopharma Advances BB-301 Gene Therapy Trial for OPMD Following Positive Safety Review
Benitec Biopharma's independent Data Safety Monitoring Board recommended continuation of the Phase 1b/2a clinical trial for BB-301 after completing safety review of all six subjects in Cohort 1.
Benitec Biopharma's BB-301 Shows Promise in OPMD Dysphagia Treatment
Benitec Biopharma's BB-301 gene therapy demonstrates durable improvements in swallowing function in OPMD patients, according to interim clinical study data.
Benitec BioPharma's Gene Therapy Shows Promising Results in Oculopharyngeal Muscular Dystrophy Trial
Benitec BioPharma reports a 35% reduction in total score on the Sydney Swallow Questionnaire in the first patient treated with their gene therapy for oculopharyngeal muscular dystrophy (OPMD).
Benitec Biopharma's BB-301 Gene Therapy Shows Swallowing Improvement in OPMD Patients
Benitec Biopharma's BB-301 gene therapy demonstrated clinically meaningful improvements in swallowing for OPMD patients in a Phase 1b/2a trial.